Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• BMO Capital analyst Connor Mackay initiated coverage on Insmed Inc (NASDAQ:INSM) with an Outperform rating and announced a price target of $192. Insmed shares closed at $107.02 on Monday. See how other analysts view this stock.
• BMO Capital analyst Malcolm Hoffman initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM) with an Outperform rating and announced a price target of $310. Axsome Therapeutics shares closed at $221.64 on Monday. See how other analysts view this stock.
• Compass Point analyst Rob Simone initiated coverage on American Healthcare REIT Inc (NYSE:AHR) with a Buy rating and announced a price target of $70. American Healthcare shares closed at $56.66 on Monday. See how other analysts view this stock.
• BMO Capital analyst Connor Murphy initiated coverage on Trevi Therapeutics Inc (NASDAQ:TRVI) with an Outperform rating and announced a price target of $36. Trevi Therapeutics shares closed at $16.77 on Tuesday. See how other analysts view this stock.
• Rodman & Renshaw analyst Seema Sheoran initiated coverage on Eledon Pharmaceuticals Inc (NASDAQ:ELDN) with a Buy rating and announced a price target of $12. Eledon Pharmaceuticals shares closed at $3.86 on Monday. See how other analysts view this stock.

Considering buying INSM stock? Here’s what analysts think:

Photo via Shutterstock